Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233402 · ClinicalTrials.gov registry record · Phase 3
Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
A Phase 3 study, sponsored by Photocure.
- Completed
- Registry status
- Phase 3
- Development phase
- 789
- Enrollment target
NCT00233402 is a Phase 3 study that has completed, run by Photocure. The registered enrollment target is 789 participants.
The verdict
NCT00233402, a Phase 3 study, has completed, sponsored by Photocure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 789 participants
- Enrollment target
Study Summary
The purpose of this study is to document the additional detection of papillary bladder cancer and the reduced early recurrence due to the improved detection and resection of these tumors after Hexvix cystoscopy compared to standard cystoscopy in patients with papillary bladder cancer.
Interventions
- DRUG Hexvix
- PROCEDURE Standard white light cystoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 789 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233402
The ClinicalTrials.gov registry entry for NCT00233402 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 789 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Photocure, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hexvix is the first listed.
NCT00233402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233402 about?
NCT00233402 is a clinical study titled "Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy". The purpose of this study is to document the additional detection of papillary bladder cancer and the reduced early recurrence due to the improved detection and resection of these tumors after Hexvix cystoscopy compared to standard cystoscopy in patients with papillary bladder cancer.
What is the current status of trial NCT00233402?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 789 participants. The study started on 2005-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00233402?
The interventions under investigation include: Hexvix (DRUG), Standard white light cystoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT00233402?
This trial is sponsored by Photocure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.